Loading...

Marc Dall'Era

Title(s)Professor, Urology
SchoolUniversity of California, Davis
Phone(916)893-7906
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF. The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. Eur Urol. 2019 Sep; 76(3):268-272. PMID: 31128968.
      View in: PubMed
    2. Dall'Era M. Editorial Comment. J Urol. 2019 05; 201(5):935-936. PMID: 30822206.
      View in: PubMed
    3. Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC. Molecular Characterization of Neuroendocrine-like Bladder Cancer. Clin Cancer Res. 2019 Jul 01; 25(13):3908-3920. PMID: 30952638.
      View in: PubMed
    4. Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP, Zhao R, Noel ODV, Tepper CG, Chen HW, Dall'Era M, Evans CP, Gao AC. Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. Nat Commun. 2018 11 16; 9(1):4700. PMID: 30446660.
      View in: PubMed
    5. Chandrasekar T, Dall'Era MA, Tilki D. Multiparametric MRI: an important tool to improve risk stratification for active surveillance in prostate cancer. BJU Int. 2018 11; 122(5):721-722. PMID: 30358932.
      View in: PubMed
    6. Rogers CR, Rovito MJ, Hussein M, Obidike OJ, Pratt R, Alexander M, Berge JM, Dall'Era M, Nix JW, Warlick C. Attitudes Toward Genomic Testing and Prostate Cancer Research Among Black Men. Am J Prev Med. 2018 11; 55(5 Suppl 1):S103-S111. PMID: 30670195.
      View in: PubMed
    7. Dall'Era MA, De Vere White RW. New Insights into Ejaculatory Frequency and Prostate Cancer Risk: Association, Causation, or What Do We Have to Lose? Eur Urol. 2018 11; 74(5):549-550. PMID: 30177292.
      View in: PubMed
    8. Stern M, Phillips JL. Editorial Comment. J Urol. 2018 11; 200(5):1003-1004. PMID: 30030970.
      View in: PubMed
    9. Dall'Era MA, Lo MJ, Chen JY, Cress R, Hamilton AS. Reply to Radiation therapy does not increase survival in addition to standard androgen deprivation therapy for metastatic prostate cancer: An old, faded picture? Cancer. 2018 09 01; 124(17):3619-3620. PMID: 29975411.
      View in: PubMed
    10. Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. World J Urol. 2019 Jan; 37(1):165-172. PMID: 29882105.
      View in: PubMed
    11. Dall'Era MA, deVere-White R, Rodriguez D, Cress R. Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015. Eur Urol Focus. 2019 Nov; 5(6):1014-1021. PMID: 29735368.
      View in: PubMed
    12. Winters BR, Vakar-Lopez F, Brown L, Montgomery B, Seiler R, Black PC, Boormans JL, Dall Era M, Davincioni E, Douglas J, Gibb EA, van Rhijn BWG, van der Heijden MS, Hsieh AC, Wright JL, Lam HM. Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. Urol Oncol. 2018 07; 36(7):342.e7-342.e14. PMID: 29657089.
      View in: PubMed
    13. Dall'Era MA, Davies BJ, Eggener S. Active surveillance for prostate cancer. Transl Androl Urol. 2018 Apr; 7(2):195-196. PMID: 29732276.
      View in: PubMed
    14. Dall'Era MA, Lo MJ, Chen J, Cress R, Hamilton AS. Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer. Cancer. 2018 05 01; 124(9):1921-1928. PMID: 29499075.
      View in: PubMed
    15. Zargar H, Shah JB, van Rhijn BW, Daneshmand S, Bivalacqua TJ, Spiess PE, Black PC, Kassouf W. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy. J Urol. 2018 06; 199(6):1452-1458. PMID: 29329894.
      View in: PubMed
    16. Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP. Genomic Markers in Prostate Cancer Decision Making. Eur Urol. 2018 04; 73(4):572-582. PMID: 29129398.
      View in: PubMed
    17. Gheibi P, Zeng S, Son KJ, Vu T, Ma AH, Dall'Era MA, Yap SA, de Vere White RW, Pan CX, Revzin A. Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells. Sci Rep. 2017 09 25; 7(1):12277. PMID: 28947782.
      View in: PubMed
    18. Dall'Era M. Editorial Comment. J Urol. 2017 08; 198(2):328. PMID: 28506736.
      View in: PubMed
    19. Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur Urol. 2017 10; 72(4):544-554. PMID: 28390739.
      View in: PubMed
    20. Dall'Era MA, Klotz L. Active surveillance for intermediate-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017 03; 20(1):1-6. PMID: 27801900.
      View in: PubMed
    21. Dall'Era M, Evans C. Genomic and Biological Markers to Select Treatment for Patients with Prostate Cancer: Choose Wisely, My Friend. J Urol. 2017 01; 197(1):8-9. PMID: 27746279.
      View in: PubMed
    22. Pan A, Zhang H, Li Y, Lin TY, Wang F, Lee J, Cheng M, Dall'Era M, Li T, deVere White R, Pan CX, Lam KS. Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer. Nanotechnology. 2016 Oct 21; 27(42):425103. PMID: 27640312.
      View in: PubMed
    23. Dall'Era MA. Reasons for Abandonment of Active Surveillance in Men with Prostate Cancer. J Urol. 2016 09; 196(3):637-8. PMID: 27316451.
      View in: PubMed
    24. Yap SA, Yuh LM, Evans CP, Dall'Era MA, Wagenaar RM, Cress R, Lara PN. Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World J Urol. 2017 Feb; 35(2):277-283. PMID: 27306686.
      View in: PubMed
    25. Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN, Pan CX. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016 06 15; 122(12):1897-904. PMID: 27019001.
      View in: PubMed
    26. Zargar H, Zargar-Shoshtari K, Lotan Y, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black P. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1? J Urol. 2016 Apr; 195(4 Pt 1):886-93. PMID: 26521718.
      View in: PubMed
    27. Belair CD, Paikari A, Moltzahn F, Shenoy A, Yau C, Dall'Era M, Simko J, Benz C, Blelloch R. DGCR8 is essential for tumor progression following PTEN loss in the prostate. EMBO Rep. 2015 Sep; 16(9):1219-32. PMID: 26206718.
      View in: PubMed
    28. Dall'Era M, Carroll P. What is the Optimal Way to Select Candidates for Active Surveillance of Prostate Cancer? J Urol. 2015 Sep; 194(3):615-6. PMID: 26079332.
      View in: PubMed
    29. Dall'Era MA. Patient and disease factors affecting the choice and adherence to active surveillance. Curr Opin Urol. 2015 May; 25(3):272-6. PMID: 25692724.
      View in: PubMed
    30. Nguyen HG, Tilki D, Dall'Era MA, Durbin-Johnson B, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Espinós EL, Mandel P, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. J Urol. 2015 Aug; 194(2):304-308. PMID: 25797392.
      View in: PubMed
    31. Tomlinson B, Lin TY, Dall'Era M, Pan CX. Nanotechnology in bladder cancer: current state of development and clinical practice. Nanomedicine (Lond). 2015; 10(7):1189-201. PMID: 25929573.
      View in: PubMed
    32. Tilki D, Kim SI, Hu B, Dall'Era MA, Evans CP. Ultrasensitive prostate specific antigen and its role after radical prostatectomy: a systematic review. J Urol. 2015 May; 193(5):1525-31. PMID: 25444980.
      View in: PubMed
    33. Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb; 67(2):241-9. PMID: 25257030.
      View in: PubMed
    34. Tilki D, Hu B, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Linares E, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Thieu W, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of synchronous metastasis distribution on cancer specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy. J Urol. 2015 Feb; 193(2):436-42. PMID: 25063493.
      View in: PubMed
    35. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer. 2014 Mar 15; 120(6):818-23. PMID: 24258693.
      View in: PubMed
    36. Tilki D, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus. Eur Urol. 2014 Sep; 66(3):577-83. PMID: 23871402.
      View in: PubMed
    37. Dall'Era MA. The economics of active surveillance for prostate cancer. Curr Opin Urol. 2013 May; 23(3):278-82. PMID: 23449496.
      View in: PubMed
    38. Dall'Era M. Editorial comment. J Urol. 2013 Jul; 190(1):96. PMID: 23624151.
      View in: PubMed
    39. Dall'Era MA, Cheng L, Pan CX. Contemporary management of muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2012 Jul; 12(7):941-50. PMID: 22845409.
      View in: PubMed
    40. Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012 Dec; 62(6):976-83. PMID: 22698574.
      View in: PubMed
    41. Kim S, Dall'Era MA, Evans CP. Economic analysis of active surveillance for localized prostate cancer. Curr Opin Urol. 2012 May; 22(3):247-53. PMID: 22388666.
      View in: PubMed
    42. Keegan KA, Dall'Era MA, Durbin-Johnson B, Evans CP. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer. 2012 Jul 15; 118(14):3512-8. PMID: 22180322.
      View in: PubMed
    43. McGahan JP, Loh S, Fitzgerald E, Koppie T, Evans CP, Dall'Era M, Li CS. Pretreatment imaging can be used to select imaging guidance, ultrasound alone versus CT plus ultrasound, for percutaneous renal radiofrequency ablation. AJR Am J Roentgenol. 2011 Nov; 197(5):1244-50. PMID: 22021521.
      View in: PubMed
    44. Dall'Era MA, Cowan JE, Simko J, Shinohara K, Davies B, Konety BR, Meng MV, Perez N, Greene K, Carroll PR. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int. 2011 Apr; 107(8):1232-7. PMID: 20804478.
      View in: PubMed
    45. Wu JN, Dall'Era MA. Active surveillance for localized prostate cancer--current practices and recommendations. ScientificWorldJournal. 2010 Dec 14; 10:2352-61. PMID: 21170486.
      View in: PubMed
    46. Davies BJ, Smaldone MC, Sadetsky N, Dall'era M, Carroll PR. The impact of obesity on overall and cancer specific survival in men with prostate cancer. J Urol. 2009 Jul; 182(1):112-7; discussion 117. PMID: 19447437.
      View in: PubMed
    47. Dall'Era MA, Carroll PR. Outcomes and follow-up strategies for patients on active surveillance. Curr Opin Urol. 2009 May; 19(3):258-62. PMID: 19295434.
      View in: PubMed
    48. Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol. 2009 Apr; 181(4):1628-33; discussion 1633-4. PMID: 19233388.
      View in: PubMed
    49. Dall'era MA, Hosang N, Konety B, Cowan JE, Carroll PR. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease. J Urol. 2009 Apr; 181(4):1622-7; discussion 1627. PMID: 19230923.
      View in: PubMed
    50. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008 Jun 15; 112(12):2664-70. PMID: 18433013.
      View in: PubMed
    51. Breyer BN, Greene KL, Dall'Era MA, Davies BJ, Kane CJ. Pelvic lymphadenectomy in prostate cancer. Prostate Cancer Prostatic Dis. 2008; 11(4):320-4. PMID: 18490935.
      View in: PubMed
    52. Dall'Era MA, Kane CJ. Watchful waiting versus active surveillance: appropriate patient selection. Curr Urol Rep. 2008 May; 9(3):211-6. PMID: 18765115.
      View in: PubMed
    53. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE, Wallace ME, Kantoff PW, Carroll PR. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008 Apr 15; 112(8):1650-9. PMID: 18306379.
      View in: PubMed
    54. Dall'Era MA, Konety BR. Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression. Nat Clin Pract Urol. 2008 May; 5(5):277-83. PMID: 18285752.
      View in: PubMed
    55. Walsh TJ, Dall'Era MA, Croughan MS, Carroll PR, Turek PJ. Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer. J Urol. 2007 Oct; 178(4 Pt 1):1440-6; discussion 1446. PMID: 17706709.
      View in: PubMed
    56. Dall'Era M, Konety B. The optimal management of clinically localized prostate cancer: the debate continues. Nat Clin Pract Urol. 2007 Sep; 4(9):474-5. PMID: 17653197.
      View in: PubMed
    57. Dall'Era MA, Oudes A, Martin DB, Liu AY. HSP27 and HSP70 interact with CD10 in C4-2 prostate cancer cells. Prostate. 2007 May 15; 67(7):714-21. PMID: 17342744.
      View in: PubMed
    58. Dall'Era M, Carroll PR. Prostate cancer--more information and more questions. J Urol. 2007 May; 177(5):1607-8. PMID: 17437768.
      View in: PubMed
    59. Dall'Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, Liu AY. Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol. 2007 Mar 02; 7:3. PMID: 17335564.
      View in: PubMed
    60. Dall'Era MA, Hampson NB, Hsi RA, Madsen B, Corman JM. Hyperbaric oxygen therapy for radiation induced proctopathy in men treated for prostate cancer. J Urol. 2006 Jul; 176(1):87-90. PMID: 16753375.
      View in: PubMed
    61. Shih SJ, Dall'Era MA, Westphal JR, Yang J, Sweep CG, Gandour-Edwards R, Evans CP. Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue. Prostate Cancer Prostatic Dis. 2003; 6(2):131-7. PMID: 12806371.
      View in: PubMed
    62. Evans CP, Stapp EC, Dall'Era MA, Juarez J, Yang JC. Regulation of u-PA gene expression in human prostate cancer. Int J Cancer. 2001 Nov 01; 94(3):390-5. PMID: 11745419.
      View in: PubMed
    63. Dall'Era M, Das S. Benign medullary fibroma of the kidney. J Urol. 2000 Dec; 164(6):2018. PMID: 11061906.
      View in: PubMed
    64. Wolf JS, Cher M, Dall'era M, Presti JC, Hricak H, Carroll PR. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol. 1995 Mar; 153(3 Pt 2):993-9. PMID: 7853590.
      View in: PubMed